Because of the fact that CTLA-4 and PD-1 play a crucial regulatory role in tumor immunoreaction process, their inhibitors have been well studied for a long period and demonstrated exciting benefit in clinical cancer therapy. The gene discussed is PDCD1; the disease is neoplasm.